MTEM Molecular Templates Inc

Molecular Templates, Inc., (Nasdaq: MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, announced today that Eric Poma, Ph.D., Chief Executive Officer and Chief Scientific Officer, will present a corporate overview at the Oppenheimer New York Oncology Insight Summit, and the UBS Global Healthcare Conference, both taking place in New York City.

Oppenheimer New York Oncology Insight Summit
Date:	Thursday, May 16
Format:	One-on-One Meetings
UBS Global Healthcare Conference
Date:	Monday, May 20
Time:	8:00am Eastern Time
Format:	Fireside Chat
Webcast:	https://cc.talkpoint.com/ubsx001/052019a_as/?entity=62_RJ1HXDS

About Molecular Templates  Molecular Templates is a clinical-stage oncology company focused on the discovery and development of differentiated, targeted, biologic therapeutics for cancer. We believe our proprietary biologic drug platform technology, referred to as engineered toxin bodies, or ETBs, provides a differentiated mechanism of action that may address some of the limitations associated with currently available cancer therapeutics. ETBs utilize a genetically engineered form of Shiga-like Toxin A subunit, or SLTA, a ribosome inactivating bacterial protein, that can be targeted to specifically destroy cancer cells.  Additional information about Molecular Templates can be obtained at http://www.mtem.com. 

Investor Contact: Adam CutlerChief Financial Officeradam.cutler@mtem.com 862-204-4006

Source: Molecular Templates, Inc.